GlobeNewswire by notified

Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation

Share
  • Biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) approved for seven indications of reference medicine Humira®*

  • With this approval, Sandoz adalimumab HCF biosimilar will offer US patients reduced injection volume in citrate-free formulation

  • Sandoz continues to expand patient access to much-needed medications, increase healthcare savings and fuel innovation through increased competition

Basel, March 21, 2023 – Sandoz, a global leader in generic pharmaceuticals and biosimilars, today announced that the US Food and Drug Administration (FDA) approved a citrate-free high-concentration formulation (HCF) of its biosimilar Hyrimoz® (adalimumab-adaz) injection.

The adalimumab citrate-free HCF (100 mg/mL) is approved to treat seven indications covered by the reference medicine, Humira®* (adalimumab), including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis and plaque psoriasis.1

Sandoz intends to launch the Hyrimoz citrate-free HCF in the US on July 1, 2023.

“As one of the first adalimumab high-concentration formulation biosimilars approved in the US, Hyrimoz HCF has the potential to expand access for millions of people who face the realities of living with a serious inflammatory disease and to enhance the patient experience,” said Keren Haruvi, President, Sandoz Inc., Head of North America.

“Sandoz has more than two decades of experience researching, developing and bringing biosimilars to markets across the globe. We are excited to continue this leadership by providing patients with another treatment option to help manage their chronic conditions.”

The FDA approval was based on a Phase I pharmacokinetics (PK) bridging study comparing the FDA-approved adalimumab 50 mg/mL to the citrate-free 100 mg/mL (HCF). This study met all of the primary objectives, demonstrating comparable PK and showing similar safety and immunogenicity of the adalimumab 50 mg/mL and adalimumab HCF.

"Biosimilars are extensively studied, FDA-approved treatments,” said Steve Taylor, president and chief executive officer, Arthritis Foundation. “There are millions of patients affected by chronic inflammatory conditions that drastically impact their everyday lives. Given the high burden of disease for these conditions, biosimilars are one potential solution for healthcare providers and patients to consider, to ensure patients can take and stay on their medicines to help manage their disease and health outcomes.”

The FDA approval of Hyrimoz HCF builds on the already approved and well-established Sandoz global biosimilar portfolio in immunology. Sandoz has nearly 120 million days of patient experience with Hyrimoz across 40 countries.2 When it launches, Hyrimoz HCF will represent the first launch of a Sandoz biosimilar in the US market in this specific disease space.

Sandoz is committed to helping millions of patients sustainably and affordably access critical and potentially life-changing biologic medicines across a range of areas including immunology, oncology, supportive care and endocrinology. Sandoz has a leading global portfolio with eight marketed biosimilars and a further 15+ in various stages of development.

Since launching the first biosimilar in the US in 2015, Sandoz has proven biosimilars create early and expanded patient access to life-altering medicines while increasing healthcare savings and creating competition that fuels innovation and development of new and enhanced treatments in areas of unmet need.

About Hyrimoz® (adalimumab-adaz)
Adalimumab, the active ingredient in Hyrimoz, is an inhibitor of tumor necrosis factor (TNF), a protein that is overproduced in certain autoimmune conditions — including rheumatoid arthritis, plaque psoriasis, Crohn's disease and ulcerative colitis — causing inflammation and tissue destruction in joints, mucosa or skin. In some cases of autoimmune disease, the immune system damages the body’s own tissues. Hyrimoz targets and blocks the protein that contributes to disease symptoms.1

Please see the full [Prescribing Information] for Hyrimoz:
Hyrimoz_Highlights_Prescribing_Information.pdf (sandoz.com)

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee that, if approved, such generic or biosimilar products will be approved for all indications included in the reference product’s label. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; the particular prescribing preferences of physicians and patients; competition in general, including potential approval of additional generic or biosimilar versions of such products; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; litigation outcomes, including intellectual property disputes or other legal efforts to prevent or limit Sandoz from selling its products; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

References
1. Hyrimoz. Prescribing Information. Available at: Hyrimoz_Highlights_Prescribing_Information.pdf (sandoz.com)
2. Data on file (PSUR)

*Humira is a registered trademark of AbbVie Biotechnology Ltd

# # #

About Sandoz
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs. Our ambition is to be the world’s leading and most valued generics company. Our broad portfolio of high-quality medicines, covering major therapeutic areas, accounted for 2022 sales of USD 9.2 billion.

Sandoz on social media:
LinkedIn: https://www.linkedin.com/company/sandoz
Twitter: https://twitter.com/sandoz_global
Facebook: https://www.facebook.com/sandozglobal/
Instagram: https://www.instagram.com/sandozglobal

CEO Richard Saynor on LinkedIn: https://www.linkedin.com/in/richard-saynor/

# # #

Sandoz Global Communications

Central North America
Chris Lewis +49 174 244 9501
chris.lewis@sandoz.com
Vicki Crafton +1 201.213.6338 (mobile)
vicki.crafton@sandoz.com

Novartis Media Relations
E-mail: media.relations@novartis.com

Central North America
Richard Jarvis +41 79 584 2326 Julie Masow +1 862 579 8456
Novartis Investor Relations
Central investor relations line:
+41 61 324 7944
E-mail: investor.relations@novartis.com

Central North America
Samir Shah +41 61 324 7944 Sloan Simpson +1 862 345 4440
Nicole Zinsli-Somm +41 61 324 3809 Parag Mahanti +1 973 876 4912
Isabella Zinck +41 61 324 7188
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

AKVA group ASA: New Land Based contract signed6.6.2023 11:08:00 CEST | Press release

AKVA is pleased to announce the award of a new RAS contract with Cermaq Norway for the 12 million post smolt facility at Sørøya in Finnmark. The estimated contract value is minimum EUR 60 million. Engineering and design work will start immediately. Knut Nesse, CEO of AKVA: “This contract with Cermaq Norway represents for AKVA the largest contract in Norway ever, and will support the activity level in our Land Based business for the next few years”. Dated: 6 June 2023 AKVA group ASA Web: www.akvagroup.com CONTACTS: Knut Nesse Chief Executive OfficerPhone:+47 51 77 85 00Mobile:+47 91 37 62 20E-mail:knesse@akvagroup.com Ronny MeinkøhnChief Financial OfficerPhone:+47 51 77 85 00Mobile:+47 98 20 67 76E-mail:rmeinkohn@akvagroup.com *** This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements according to section 5-12 of the Norwegian Securities Trading Act. The information was submitted for publication by

DSV, 1037 - SHARE BUYBACK IN DSV A/S6.6.2023 11:01:53 CEST | Press release

Company Announcement No. 1037 On 27 April 2023, we initiated a share buyback programme, as described in Company Announcement No. 1031. According to the programme, the company will in the period from 27 April 2023 until 24 July 2023 purchase own shares up to a maximum value of DKK 4,500 million, and no more than 5,000,000 shares, corresponding to 2.28% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Trading dayNumber of shares bought backAverage transaction priceAmount DKKAccumulated trading for days 1-19937,6391,310.771,229,030,13420:30 May 202361,5321,350.7083,111,23521:31 May 202361,0971,343.4182,078,38922:1 June 202380,7471,343.36108,472,20123:2 June 202380,7101,362

Transactions in connection with share buyback programme6.6.2023 11:00:00 CEST | Press release

On 27 April 2022, Tryg A/S (“Tryg”) announced that a share buyback programme of DKK 5.0 billion had been initiated as a result of the sale of Codan Denmark. The share buyback programme is executed in accordance with EU Market Abuse Regulation, EU Regulation no. 596/2014 of 16 April 2014 and the provisions of Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Regulation”). The share buyback programme will end no later than 03 July 2023. Transactions made under the share buyback programme will be announced through Nasdaq Copenhagen on a weekly basis. The following transactions have been executed in the period 30 May 2023 to 02 June 2023: Number of sharesAvg. purchase price, DKKTransaction value, DKK30 May 2023 40,000 159.74 6,389,60031 May 2023 50,000 158.86 7,943,00001 June 2023 50,000 157.98 7,899,00002 June 2023 70,000 157.74 11,041,800Accumulated for the period210,000-33,273,400Accumulated under the programme30,434,000-4,861,506,740 Detailed information

Kitron: Ny aksjekapital registrert6.6.2023 10:58:43 CEST | Pressemelding

(2023-06-06) Det vises til børsmelding fra Kitron ASA 1. juni 2023 vedrørende utstedelse av 526 081 nye aksjer under Selskapets aksjeinsentivprogram. Kapitalforhøyelsen i forbindelse med aksjeinsentivprogrammet har i dag blitt registrert i Foretaksregisteret. Registrert aksjekapital i Kitron ASA etter registreringen er NOK 19 821 713,40 fordelt på 198 217 134 aksjer hver pålydende NOK 0.10. Hver aksje gir én stemme på Selskapets generalforsamling. Kitron er et ledende skandinavisk foretak innen produksjon av elektronikk og relaterte tjenester for sektorene Konnektivitet, Elektrifisering, Industri, Medisinsk utstyr og Forsvar/Luftfart. Konsernet har virksomhet i Norge, Sverige, Danmark, Litauen, Tyskland, Polen, Tsjekkia, India, Kina og USA. Kitron har rundt 3 200 ansatte, og driftsinntektene var EUR 641 million i 2022. www.kitron.com (http://www.kitron.com) Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12.

Kitron: New share capital registered6.6.2023 10:58:43 CEST | Press release

(2023-06-06) Reference is made to the stock exchange announcement from Kitron ASA on 1 June 2023 regarding issuance of 526,081 new shares under the Company's share incentive program. The share capital increase in connection with the share incentive program has been registered in the Norwegian Register of Business Enterprises today. Registered share capital in Kitron ASA following the registration is NOK 19,821,713.40 divided on 198,217,134 shares, each with a par value of NOK 0.10. Each share gives one vote at the company's general meeting. Kitron is a leading Scandinavian electronics manufacturing services company for the Connectivity, Electrification, Industry, Medical devices and Defence/Aerospace sectors. The group is located in Norway, Sweden, Denmark, Lithuania, Germany, Poland, the Czech Republic, India, China and the United States. Kitron has about 3 200 employees, and revenues were EUR 641 million in 2022. www.kitron.com (http://www.kitron.com) This information is subject to t